Strong pharmaceutical demand drives the development of pharmaceutical machines, and many companies such as Canaan Technology have achieved gratifying performance

[Pharmaceutical Network Market Analysis] In recent years, with the active innovation and upgrading of pharmaceutical equipment companies and the strong demand in the downstream pharmaceutical industry, some pharmaceutical equipment industry companies have performed well
.

For example, on February 28, Canaan Technology disclosed its 2021 performance report.
In 2021, the company's operating income increased by 5.
20% year-on-year to 1.
060 billion yuan; the net profit attributable to shareholders of the listed company increased by 12.
15% year-on-year to 76.
15 million yuan
.

Regarding the changes in performance, Canaan Technology said that during the reporting period, the company continued to steadily improve the operational efficiency of various businesses, optimize the revenue structure, and coordinate the development of upstream and downstream businesses in the entire industry chain to ensure the company's oral solid preparation equipment, biological preparation fluid equipment and various businesses.
The segment continued to maintain steady development; at the same time, the company continued to increase its efforts to develop new markets and invest in new product research and development, strengthen brand effects and the construction of marketing network channels, among which the rapid growth of research and development expenses affected the net profit
.

During the reporting period, the demand from the downstream pharmaceutical industry was relatively strong, resulting in a steady increase in project orders
.

On the evening of February 25, Nano Micro Technology released the 2021 performance report, showing that in 2021, Nano Micro Technology’s operating income will increase by 117.
74% year-on-year to 446 million yuan; the net profit attributable to the parent will increase by 158.
75% year-on-year to 188 million yuan; the company relies on Nano Micro The technological innovation advantage of ball bottom layer preparation has accumulated and formed a relatively complete product line, large-scale production capacity and professional and efficient application technical service capacity, which supports the rapid growth of the company's performance
.

 　　In addition, according to the 2021 annual performance forecast previously released by Chutian Technology, the company expects that its performance in 2021 will increase in the same direction, that is, the net profit attributable to shareholders of the listed company during the reporting period will increase by 149.
33%-199.
20% year-on-year, approximately 500 million yuan – 600 million yuan
.

 　　During the reporting period, the company focused on the development of biopharmaceutical equipment, and has basically completed the layout of biopharmaceutical front-end equipment, including stainless steel reactors, disposable reactors and their consumables, separation and purification chromatography systems, stock solution preparation, biomacromolecule microsphere fillers, etc.
Wait
.

At the same time, the synergy between various subsidiaries has been strengthened, and the company's competitiveness, service capabilities and market development capabilities have been improved, and great achievements have been made in the high-end market and import substitution.
boost
.

 　　It is understood that in recent years, Chutian Technology has adhered to the strategy of "one vertical, one horizontal and one platform", continued to increase investment in R&D and manufacturing technology, continuously expanded its product series, and is transitioning to smart medical technology solutions
.

 　　Tofflon also previously released a performance forecast for 2021.
According to its performance forecast, Tofflon is expected to achieve a year-on-year increase of 65% to 95% in net profit in 2021, about 765 million to 904 million yuan
.

 　　Regarding the reasons for the changes in performance, the announcement stated that during the reporting period, Tofflon adopted the business model of "equipment + engineering + consumables" around the development strategy of "systematization, internationalization, and digitalization", and vigorously promoted the layout of the three major sectors and Invest to provide global customers with forward-looking and competitive system solutions in the field of pharmaceutical equipment, food equipment, and cell therapy equipment
.

On the business side, the new products and new markets deployed by Tofflon's business segments over the years have gradually shown results, and segments such as injections and solid preparations have grown steadily; segments such as biological macromolecules and cell equipment have grown rapidly
.

 　　Analysts said that in recent years, the growth rate of China's pharmaceutical manufacturing assets has begun to rise.
Under the trend of rapid development of the pharmaceutical industry and the localization of the supply chain, the upstream pharmaceutical equipment industry has ushered in rapid growth
.

 　　It is understood that China's pharmaceutical equipment industry started in the 1990s.
In recent years, the rapid development of China's biopharmaceutical industry has driven the acceleration of fixed asset investment in biopharmaceutical enterprises
.

At the same time, domestic pharmaceutical equipment enterprises have made breakthroughs in the research and development and production of biological pharmaceutical equipment, the import substitution of domestic pharmaceutical equipment has accelerated, and the industry has ushered in rapid development
.

 Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.